These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26281693)

  • 21. [Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC].
    Brosseau S; Oulkhouir Y; Naltet C; Zalcman G
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S27-33. PubMed ID: 26118873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer.
    Kuwano M; Sonoda K; Murakami Y; Watari K; Ono M
    Pharmacol Ther; 2016 May; 161():97-110. PubMed ID: 27000770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging treatment for advanced lung cancer with EGFR mutation.
    Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
    Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.
    Lee DH
    Pharmacol Ther; 2017 Jun; 174():1-21. PubMed ID: 28167215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.
    Zhu VW; Klempner SJ; Ou SI
    Trends Cancer; 2019 Nov; 5(11):677-692. PubMed ID: 31735287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
    Takeuchi S; Yano S
    Respir Investig; 2014 Nov; 52(6):348-56. PubMed ID: 25453378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.
    Karachaliou N; Rosell R; Morales-Espinosa D; Viteri S
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):807-15. PubMed ID: 24611674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
    Isozaki H; Ichihara E; Takigawa N; Ohashi K; Ochi N; Yasugi M; Ninomiya T; Yamane H; Hotta K; Sakai K; Matsumoto K; Hosokawa S; Bessho A; Sendo T; Tanimoto M; Kiura K
    Cancer Res; 2016 Mar; 76(6):1506-16. PubMed ID: 26719536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
    Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of patients with ALK gene rearranged non-small cell lung cancer 
after resistance to crizotinib].
    Jiang T; Zhou C
    Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):69-74. PubMed ID: 25676398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options.
    Piotrowska Z; Sequist LV
    Cancer J; 2015; 21(5):371-7. PubMed ID: 26389761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
    Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
    BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acquired resistance in oncogene-addicted non-small-cell lung cancer.
    Sini C; Tuzi A; Rossi G; Russo A; Pezzuto A
    Future Oncol; 2018 Jun; 14(13s):29-40. PubMed ID: 29989451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress.
    Castellanos EH; Horn L
    Curr Treat Options Oncol; 2015 Oct; 16(10):51. PubMed ID: 26364032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM; Wozniak A
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
    Suda K; Murakami I; Sakai K; Tomizawa K; Mizuuchi H; Sato K; Nishio K; Mitsudomi T
    Lung Cancer; 2016 Jan; 91():36-40. PubMed ID: 26711932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.